Talniflumate

Drug Profile

Talniflumate

Alternative Names: BA 7602-06; LOMUCIN; MSI 1995

Latest Information Update: 02 Sep 2014

Price : $50

At a glance

  • Originator Bago
  • Class Antiasthmatics; Antirheumatics; Benzofurans; Nonsteroidal anti-inflammatories; Pyridines; Small molecules
  • Mechanism of Action Mucin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Cystic fibrosis; Gastrointestinal disorders

Most Recent Events

  • 28 May 2008 Talniflumate is available for licensing (http://www.genaera.com/business_development.php)
  • 05 Jul 2007 Discontinued - Phase-II for Cystic fibrosis in Ireland (PO)
  • 19 Apr 2005 No development reported - Phase-I for Asthma in Mexico (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top